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A B S T R A C T
Background: While statins may have anti-inﬂammatory eﬀects, anti-oxidative eﬀects are controversial. We in-
vestigated if statin treatment is associated with diﬀerences in oxidatively generated nucleotide damage and
chronic inﬂammation, and the relationship between nucleotide damage and chronic inﬂammation.
Methods: We included 19,795 participants from the Danish General Suburban Population Study. In 3420 par-
ticipants, we measured urinary 8-oxodG and 8-oxoGuo by liquid chromatography-tandem mass spectrometry as
markers of oxidatively generated damage to DNA and RNA, respectively. We used a composite score for chronic
inﬂammation (INFLA score) of hsCRP, WBC, platelet count, and neutrophil granulocyte to lymphocyte ratio.
Associations were assessed using multivariate linear regression models.
Results: Compared with non-users, statin users had 4.3–6.0% lower 8-oxodG in three separate models
(p < 0.05); there were no diﬀerences in 8-oxoGuo. Among participants aged> 60 y, statin users had 11.4%
lower 8-oxodG (95%CI: 6.7–15.9%, pinteraction<0.001) and 3.9% lower 8-oxoGuo (95%CI: 0.1–7.5%, pinteraction
=0.002), compared with non-users. Compared with non-users, statin users had 11.1% (95%CI: 5.4–16.5%,
pinteraction< 0.001) lower 8-oxodG in participants treated for hypertension, and 18.6% (95%CI: 6.8–28.9%,
pinteraction<0.001) lower 8-oxodG in participants with decreased renal function. Compared with non-users, statin
users had signiﬁcantly lower INFLA score (p < 0.001). 8-oxodG and 8-oxoGuo associated positively with
markers of chronic inﬂammation.
Conclusions: Oxidatively generated DNA damage and inﬂammatory burden are lower in statin users compared
with non-users. Together, anti-oxidative and anti-inﬂammatory eﬀects may contribute to the beneﬁcial eﬀects of
statins.
1. Introduction
Statin treatment reduces the risk of cardiovascular events and death
[1]. This eﬀect is mainly due to improvement of cholesterol levels, but
may also be mediated by pleiotropic eﬀects of statins decreasing
chronic inﬂammation and oxidative stress [2,3]. Oxidative stress is
deﬁned as an imbalance between the production of reactive oxygen
species (ROS) and their elimination by anti-oxidants [4].
Markers of oxidatively generated DNA and RNA damage, as mea-
sures of intranuclear and cytosolic oxidative damage, may have clinical
relevance as markers of total systemic reactive oxidative stress [4].
Oxidatively generated damage to DNA and RNA can be quantiﬁed in
urine by measuring 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG)
and 8-oxo-7,8-dihydroguanosine (8-oxoGuo), respectively, by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) [4]. The exact
source of 8-oxodG and 8-oxoGuo is still debatable. However, the cur-
rent acceptable interpretation is that they reﬂect the rate of guanine
oxidation in the nucleic acids and their precursor pools [5–8]. Increased
levels of 8-oxodG and 8-oxoGuo are associated with aging, smoking,
type 2 diabetes mellitus (T2DM), hypertension, neurodegenerative
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diseases, cardiovascular disease (CVD) and certain cancers [4,9–12].
While studies in vivo have shown that statin treatment has anti-
inﬂammatory eﬀects [2,13], data on their anti-oxidative eﬀects in vivo
are ambiguous. Anti-oxidative eﬀects of statins have been reported in
numerous studies, while other studies have shown no such eﬀects
(Supplemental table S1) [14–19]. Notably, several diﬀerent methods
have been used to assess the level of oxidative stress, and there are
concerns regarding the validity, speciﬁcity and clinical relevance of
some of these [4]. Furthermore, these studies have been relatively
small, being powered to detect relatively large eﬀects of statin treat-
ment. Anti-inﬂammatory eﬀects of statins have also been observed as
decreases in high-sensitivity C-reactive protein (hsCRP) levels and
white blood cell count (WBC) [2,13,20–23]. Statins may also decrease
oxidative stress by reducing upstream chronic inﬂammation [24].
We investigated the diﬀerences in oxidatively generated nucleotide
damage and chronic inﬂammation between statin users and non-users
in participants from the Danish General Suburban Population Study
(GESUS).
2. Materials and methods
2.1. Study setting
GESUS is a cross-sectional study of the adult population in a sub-
urban municipality in Denmark. Participants were included 2010–2013
[25]. All individuals aged> 30 y and a random 25% selection of the
population aged 20–30 y were invited. Participation rate was 43%;
median age was 56 y. One of the main objectives of the study was to
identify risk factors for cardiovascular disease.
The study was approved by the Regional Ethical Committee (SJ-114
amendment 4) and the Danish Data Protection Agency. The principles
of The Declaration of Helsinki were abided by. Participants gave
written informed consent.
2.2. Study population
All participants in GESUS (n=21,205) were evaluated. Since our
aim was to investigate associations with chronic inﬂammation, all
participants suspected of having an acute inﬂammatory reaction were
excluded by the following criteria: hsCRP> 10mg/l or
WBC> 20×109/L or WBC< 3×109/L or missing hsCRP or WBC
(n=921); 20,284 participants were included.
For analysis of the associations of statin treatment, participants
without information about use of statins were excluded (n= 489), re-
ducing the number of participants to 19,795. To investigate the asso-
ciations between statin treatment and markers of oxidatively generated
nucleotide damage, only participants with information on statin use
who gave a urine sample were included (n=3420). All participants
who gave a urine sample (n= 3496) were included in analyses of the
associations between oxidatively generated damage and inﬂammatory
variables.
2.3. Questionnaire
A self-administered questionnaire was used in GESUS [25]. Statin
users were identiﬁed as participants giving a positive answer to the
question “Do you daily or almost daily take medicine for high choles-
terol?”. Smoking habits were reported both by smoking status (current
smoker, former smoker and never smoker), and by self-reported pack
years. Participants with hypertension were identiﬁed as those using
antihypertensive drugs. Participants with type 1 diabetes mellitus were
identiﬁed as those with diabetes diagnosed before the age of 10 y using
insulin. The remaining participants with self-reported diabetes were
regarded as having T2DM. A history of ischemic disease was deﬁned as:
previous acute myocardial infarction, ischemic heart disease and/or
stroke. The questionnaire contained no question allowing identiﬁcation
of patients with peripheral artery disease or other ischemic diseases.
Leisure time physical activity was reported in four categories: (I) mainly
passive or light activity less than 2 h/wk., (II) light activity 2–4 h/wk.,
(III) light activity> 4 h/wk. or more strenuous activity 2–4 h/wk., (IV)
more strenuous activity> 4 h/wk.
2.4. Clinical and biochemical data
Height was measured without shoes on a stadiometer. Waist cir-
cumference was measured at the lowest rib and hip circumference at
the widest part of the hip. Weight was measured on a Bio Impedance
Analysis (TANITA MC-180MA; Tanita Corporation). Participants with a
pacemaker and pregnant women were weighed on an ordinary digital
weight scale (Tanita WB-110 MA; Tanita Corporation); 1 kg was sub-
tracted to account for clothes. Body mass index (BMI) was calculated by
weight/height (kg/cm2). BMI was grouped as: normal (18.5–24.9 kg/
cm2), underweight (< 18.5 kg/cm2), overweight (25.0–29.9 kg/cm2),
obese cl I. (30.0–34.9 kg/cm2), obese cl. II (35.0–39.9 kg/cm2) and
obese cl. III (≥40 kg/cm2). Waist-to-hip ratio (WHR) was calculated as
waist circumference (cm)/hip circumference (cm).
Non-fasting blood samples were drawn 15:30–21:00 and kept at 4 °C
until biochemical analysis the next day. Blood for lipoproteins (total
cholesterol, triglycerides), creatinine and hsCRP measurements was
drawn in plasma separation tube and analyzed on Cobas-6000 (Roche
Diagnostics); blood for hematology was drawn in EDTA tubes and
analyzed on a Sysmex XE-5000 (Sysmex Corporation). Low-density li-
poprotein (LDL-C) was calculated using Friedewald equation. Estimated
glomerular ﬁltration rate (eGFR) was calculated using the Modiﬁcation
of Diet in Renal Disease (MDRD) equation.
Spot urine samples were collected from 3653 randomly selected
participants and stored at − 80 °C. Urinary 8-oxoGuo and 8-oxodG le-
vels were measured using ultra-performance LC-MS/MS on an Acquity
UPL I-class system (Waters) and Xevo TQ-S triple quadrupole mass
spectrometer (Waters) [26]. The measurements were adjusted for ur-
inary creatinine concentration and reported in nmol/mmol creatinine.
INFLA score is a scoring system for low-grade chronic inﬂammation
based on 10-tiles of hsCRP, WBC, platelet count, and neutrophil gran-
ulocyte to lymphocyte ratio (NLR) [27]. Cut-oﬀ values are shown in
Supplemental Fig. S1.
2.5. Statistical analyses
The statistical software R.3.2.3 (R Foundation for Statistical
Computing) and RStudio 1.0.136 (RStudio) were used. Summary sta-
tistics were presented as frequency and percentages for categorical
data, mean and standard deviation (SD) for numeric normally dis-
tributed data, and median and interquartile range for numeric non-
normally distributed data. Distributions of numerical data were visually
assessed and transformed using the natural logarithm (log) accordingly.
The following outcome variables were log-transformed: hsCRP, NLR, 8-
oxodG and 8-oxoGuo (Supplemental Fig. S2).
The most frequent missing data were smoking status (5%), eGFR
(4%), leisure time physical activity (2%) and information regarding
ischemic diseases and T2DM (1%). We imputed missing covariate data
by multiple imputation using the MICE R package [28]; outcome or
explanatory variables were not imputed. The associations were assessed
using multivariate linear regression models and presented in tables with
forest plots. Estimates of the diﬀerence between groups, 95% con-
ﬁdence intervals and p-values were presented; log-transformed vari-
ables were transformed back using the exponential function. Statistical
signiﬁcance was deﬁned as p-values< 0.05.
The associations between statin use and urinary 8-oxodG and 8-
oxoGuo levels were assessed using three models. In model 1 we ad-
justed for: sex, age, smoking habits, LDL-C, HDL-C, BMI group, WHR,
T2DM, hypertension, ischemic disease, eGFR and INFLA score. In model
2 we excluded INFLA score. In model 3 we used the variables known to
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aﬀect urinary 8-oxodG and 8-oxoGuo levels: sex, age, smoking habits,
BMI groups, WHR and T2DM. We also included LDL-C and HDL-C in all
models to investigate the associations independent of cholesterol levels.
Subgroup analyses were done using the third model.
The associations between statin use and inﬂammatory markers were
assessed. Included covariates were sex, age, smoking habits, BMI, WHR,
hypertension, T2DM, ischemic diseases, eGFR, LDL-C and HDL-C. In the
forest plot, diﬀerences are shown in number of SDs. Subgroup analysis
was done for the INFLA score.
Analysis of the associations between urinary 8-oxodG and 8-oxoGuo
levels and inﬂammatory markers included the following covariates: sex,
age, smoking habits, BMI, WHR, hypertension, T2DM, ischemic disease,
LDL-C and HDL-C. Estimates represent diﬀerences in the oxidative
marker per one SD increase in the inﬂammatory markers.
3. Results
In this study, 551 statin users and 2869 non-users gave a urine
sample for analysis of 8-oxodG and 8-oxoGuo levels; their character-
istics are presented in Table 1. In total, 2922 statin users, and 16,873
non-users were included for analysis of inﬂammatory markers; their
characteristics are presented in Supplemental table S1. Descriptive re-
sults are shown in Supplemental table S2.
In model 1, adjusting for INFLA score along with traditional risk
factors for CVD, statin users had 4.3% (95%CI: 0.2–8.3%, p=0.041)
lower 8-oxodG levels than non-users (Fig. 1). In model 2, only adjusting
for traditional risk factors for CVD, statin users had 4.5% (95%CI:
0.3–8.4%, p=0.035) lower 8-oxodG levels than non-users. In model 3,
only adjusting for sex, age, smoking habits, BMI, WHR, T2DM and
cholesterol levels, statin users had 6.0% (95%CI: 2.1–9.7%, p=0.003)
lower 8-oxodG levels. In subgroup analysis of model 3, we found
modiﬁcations of age, hypertension and eGFR (all pinteraction<0.001) on
the association between statin use and 8-oxodG levels. In participants
aged ≥ 60 y, statin users had 12.5% (95%CI: 7.9–16.9%) lower 8-
oxodG levels than non-users. In participants treated for hypertension,
statin users had 11.1% (95%CI: 5.4–16.5%) lower 8-oxodG levels than
non-users. In participants with eGFR< 60 µmol/l, the levels of 8-
oxodG statin users were 18.6% (95%CI: 6.8–28.9%) lower than those of
non-users (Fig. 2).
The 8-oxoGuo levels did not diﬀer between the groups in the entire
population (Fig. 1). In the subgroup analysis, we found modiﬁcations of
age (pinteraction =0.002) on the association between statin use and 8-
oxoGuo levels. In participants aged ≥ 60 y, statin users had 4.4%
(95%CI: 0.8–8.0) lower 8-oxoGuo levels than non-users (Supplemental
Fig. S3).
No diﬀerences were found between long term use of statins (> 1 y)
and short-term use of statins (≤1 y) with respect to 8-oxodG (diﬀer-
ence: −2.2%, 95%CI: −9.5 to 5.7%, p=0.573) and 8-oxoGuo levels
Table 1
Characteristics of participants with measurements of oxo8dG and oxo8Guo by
statin use.
Non-users
(n= 2869)
Statin users
(n= 551)
p-value
Sex (male), n (%) 1139 (40) 266 (48) < 0.001
Age, mean (SD) 52 (13) 64 (9) < 0.001
Current smoking status, n (%) <0.001
Never 1181 (41) 165 (30)
Former 1060 (37) 262 (48)
Smoker 479 (17) 101 (18)
Pack years median (IQR) 0.6 (0.0, 16.0) 8.8 (0.0, 28.8) < 0.001
BMI groups, n (%)* <0.001
Normal 1159 (40) 147 (27)
Underweight 31 (1) 3 (1)
Overweight 1131 (39) 253 (46)
Obese cl. I 414 (14) 108 (20)
Obese cl. II 99 (4) 31 (6)
Obese cl. III 29 (1) 6 (1)
Waist hip ratio, mean (SD) 0.91 (0.86) 0.94 (0.09) 0.455
Hypertension, n (%) 480 (17) 346 (63) < 0.001
Type 2 diabetes, n (%) 48 (2) 100 (18) < 0.001
HbA1c (mmol/mol), median
(IQR)
37 (34, 39) 40 (37, 43) < 0.001
Ischemic disease, n (%)† 48 (1.7) 144 (26.1) < 0.001
Stroke, n (%) 30 (1.0) 53 (9.6) < 0.001
Myocardial infarction, n
(%)
14 (0.5) 63 (11.4) < 0.001
Ischemic heart disease, n
(%)‡
12 (0.4) 67 (12.2) < 0.001
Cancer, n (%)§ 159 (5.5) 74 (13.4) < 0.001
Total cholesterol (mmol/l),
mean (SD)
5.57 (1.01) 4.85 (1.06) < 0.001
LDL-C (mmol/l), mean (SD) 3.21 (0.87) 2.41 (0.88) < 0.001
HDL-C (mmol/l), mean (SD) 1.61 (0.49) 1.56 (0.49) 0.014
eGFR (µmol/l), median (IQR) 82 (72, 91) 76 (65, 87) < 0.001
Leisure time physical activity, n (%)ǁ 0.001
Group I: Mainly passive
activity
149 (5) 33 (6)
Group II: Light activity 1364 (48) 292 (53)
Group III: Moderate activity 1159 (40) 185 (34)
Group IV: Strenous activity 150 (5) 22 (4)
BMI, body mass index; HbA1c, glycated hemoglobin; LDL-C, low density lipo-
protein cholesterol; HDL-C, high density lipoprotein cholesterol; eGFR, esti-
mated glomerular ﬁltration rate.
* BMI groups: Normal, 18.5–24.9 kg; Underweight, < 18.5 kg; Overweight,
25.0–29.9 kg; Obese cl. I, 30.0–34.9 kg; Obese cl. II, 35.0–39.9 kg; Obese cl. III,
≥ 40 kg.
† Ischemic heart disease or prior myocardial infarction or prior stroke.
‡ Arteriosclerosis without prior myocardial infarction.
§ Current or prior cancer diagnosis.
ǁ Leisure time physical activity groups: Group I, mainly passive or light ac-
tivity less than 2 h /wk.; Group II, light activity 2–4 h /wk.; Group III, light
activity> 4 h /wk. or more strenuous activity 2–4 h /wk.; Group IV, more
strenuous activity> 4 h /wk.
Fig. 1. Relative diﬀerence in creatinine adjusted 8-oxodG and 8-oxoGuo be-
tween statin users and non-users by multivariate liner regression models. A
negative % diﬀerence represents a lower value of creatinine adjusted 8-oxodG/
8-oxoGuo in statin users compared to non-users. Model 1: adjusted for sex, age,
smoking habits, LDL-C, HDL-C, BMI, hip-waist ratio, T2DM, hypertension, is-
chemic disease, eGFR, INFLA score. Model 2: adjusted for sex, age, smoking
habits, LDL-C, HDL-C, BMI, hip-waist ratio, T2DM, hypertension, ischemic
disease, eGFR. Model 3: adjusted for sex, age, smoking habits, LDL-C, HDL-C,
BMI, hip-waist ratio, T2DM.
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(diﬀerence: −3.9%, 95%CI: −9.4 to 1.9%, p=0.179).
Compared with non-users, the INFLA score of statin users was 0.49
(95%CI 0.22–0.76, p < 0.001) lower. Compared with non-users, statin
users had 13% (95%CI: 9–16%, p < 0.001) lower hsCRP, 0.01 109/L
(95%CI: 0.00–0.02, p=0.009) higher monocyte count, 0.05 109/L
(95%CI: 0.02–0.09, p < 0.001) higher lymphocyte count and 3%
(95%CI: 1–5%, p=0.003) lower NLR. We found no diﬀerence between
the groups with respect to WBC, neutrophil or platelet count (Fig. 3). In
subgroup analysis, we found that the association between statin use and
INFLA score was modiﬁed by BMI (pinteraction=0.010), LDL-C
(pinteraction=0.049) and eGFR (pinteraction=0.038). The biggest diﬀer-
ences were observed in participants with BMI ≥ 30 kg/cm2, partici-
pants with LDL-C≤ 3mmol/L and participants with eGFR< 60 µmol/l
(Supplemental Fig. S4).
8-oxodG was positively associated with INFLA score, WBC, mono-
cyte count, neutrophil count and NLR, but not with hsCRP, lymphocyte
count or platelet count (Fig. 4A). 8-oxoGuo was positively associated
with hsCRP, but not with INFLA score or other components of the
INFLA score (Fig. 4B).
4. Discussion
In this cross-sectional general population study, we examined the
associations between statin treatment, oxidatively generated DNA and
RNA damage, and markers of chronic inﬂammation.
In three separate models, we found that urinary 8-oxodG levels of
statin users were 4.3–6.0% lower than those of non-users, indicating
that statins decrease oxidatively generated DNA damage. The sig-
niﬁcant diﬀerences, both before and after exclusion of the INFLA score,
suggests that anti-inﬂammatory mechanisms contribute to, but are not
solely responsible for, the protective eﬀect of statins on DNA damage.
This ﬁnding is supported by the association between urinary 8-oxodG
levels and INFLA score observed in our study, and between 8-oxodG
levels and inﬂammatory markers in other smaller studies using ELISA
measurements of 8-oxodG [29,30].
In the subgroup analyses, we found that statin treatment had the
greatest protective eﬀect on DNA damage in participants aged ≥ 60 y,
in participants with hypertension and in participants with decreased
renal function. Moreover, in participants aged≥ 60 y statins also had a
protective eﬀect on RNA damage. These results indicate that the anti-
oxidative eﬀects of statins are most prominent in individuals with
higher levels of oxidative stress, which is associated with aging, hy-
pertension and decreased renal function [9,11,31]. Interestingly, anti-
hypertensive treatment has been shown to decrease urinary 8-oxodG
levels, and the interaction observed in our study may reﬂect a sy-
nergistic eﬀect between the antihypertensive treatment and statins
[11].
Two RCTs did not ﬁnd an eﬀect of statin treatment on oxidatively
generated nucleotide damage. Rasmussen et al. found no eﬀects of
statin treatment on urinary 8-oxoGuo or 8-oxodG levels in healthy men
aged 18–50 y [19]. Likewise, we found no diﬀerences in 8-oxodG and 8-
oxoGuo levels between statin users and non-users in participants
aged< 60 y or in participants without hypertension (Fig. 2), implying
a limited eﬀect of statins on oxidatively generated nucleotide damage in
Fig. 2. Subgroup analysis of the re-
lative diﬀerence in creatinine adjusted
8-oxodG between statin users and non-
users with signiﬁcance level of inter-
action by multivariate linear regression
models. A negative % diﬀerence re-
presents a lower value of creatinine
adjusted 8-oxodG in statin users com-
pared to non-users. P-value< 0.05
represents a signiﬁcant interaction.
The association is adjusted for: sex,
age, smoking habits, LDL-C, HDL, BMI,
hip-waist ratio, T2DM. BMI is in kg/
m2. Leisure time physical activity
groups: Group I, mainly passive or light
activity less than 2 h/wk.; Group II,
light activity 2–4 h/wk.; Group III,
light activity> 4 h/wk. or more
strenuous activity 2–4 h/wk.; Group
IV, more strenuous activity> 4 h/wk.
LDL-C is in mmol/l. eGFR is in µmol/l.
BMI, body mass index; T2DM, type 2
diabetes mellitus; eGFR, estimated
glomerular ﬁltration rate.
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otherwise healthy individuals. Notably, their study was powered to-
ward a 20% diﬀerence and 8-oxodG levels were about 4% lower in the
statin group, which is like the diﬀerence observed in our study. Ad-
ditionally, Scheﬀer et al. found no signiﬁcant change in 8-oxodG levels
after 12 wks. of treatment with atorvastatin or simvastatin in in-
dividuals at high risk of CVD, although nominal reductions of 6% and
16% were observed [18]. No power analysis was reported in that study.
We performed a post-hoc power analysis based on the SD of change in
8-oxodG levels published [18], a signiﬁcance level of 0.05 and a power
of 0.8. We found that their study was powered to detect diﬀerences
larger than 27%.
Supporting our ﬁndings, Abe et al. found that rosuvastatin treat-
ment for 6 mos. decreased urinary 8-oxodG levels, measured with
ELISA, by 15% in individuals with diabetic nephropathy compared with
placebo [17], which is similar to our ﬁndings in participants with de-
creased renal function. 8-oxodG has frequently been measured by
ELISA. This method lacks speciﬁcity and sensitivity, and results based
on this method should be interpreted with caution [4,5]. In a European
study, the ELISA method had higher inter-laboratory and -individual
variability than LC-MS/MS, and the agreement between ELISA and LC-
MS/MS was poor [32].
We observed diﬀerential eﬀects on DNA and RNA oxidation, a
phenomenon also observed after intervention with olive oil [33]. A
recent study also found such a diﬀerential eﬀect in diseases, however,
favoring RNA oxidation as a marker [6]. The underlying mechanisms
for the diﬀerences between DNA and RNA oxidation are not known in
detail, and the exact origin of the oxidized nucleotides is still unclear
[7,8]. Some of the diﬀerences may relate to the localization of RNA in
the cytosol and DNA in the nucleus and to the single strand properties
of RNA, versus the double strand properties of DNA and it protective
histone proteins [6]. Also, the sources of free radical production from
diﬀerent sites within the cells may have diﬀerential eﬀects on the
markers, e.g. mitochondria versus endoplasmatic reticulum, and re-
active iron structures located in the cytosol [6]. It is unknown whether
statins have diﬀerential antioxidative eﬀects in diﬀerent locations
within the cell. However, statin treatment is associated with mi-
tochondrial dysfunction in skeletal muscle cells, induced by a decrease
in coenzyme Q10 [34]. Mitochondrial dysfunction could result in in-
creased oxidatively generated damage to RNA [34]. The measurements
represent an average oxidatively generated nucleotide damage in all
tissues of the organism [5]. Therefore, the eﬀect on 8-oxoGuo by in-
creased oxidation in the muscles due to mitochondrial dysfunction may
attenuate a possible antioxidative eﬀect of statins in other tissues, when
using this method.
Taken together, our ﬁndings indicate that statins inﬂuence oxida-
tively generated DNA damage with increasing age. Moreover, anti-
oxidative eﬀects of statins may be more beneﬁcial in some high-risk
groups. Indeed, anti-inﬂammatory eﬀects of statins, measured as a de-
crease in hsCRP levels, is markedly bigger in secondary prevention
trials compared with primary prevention trials and general population
studies [13,20–23].
Statins may protect the vascular system from oxidative damage. In
the CLARICOR study two wks. of clarithromycin treatment, in in-
dividuals with ischemic heart disease, increased long-term mortality
primarily due to increased cardiovascular mortality [35], possibly due
to increased oxidatively generated damage [36]. Indeed, in a RCT, one
week of clarithromycin treatment resulted in increases of 22% in ur-
inary 8-oxodG levels and 15% in urinary 8-oxoGuo levels [36]. In later
subgroup analysis of the CLARICOR study the negative eﬀect was at-
tenuated in individuals receiving statin at baseline, implying a protec-
tive eﬀect of statins [37]. Also, in individuals with chronic kidney
disease, associated with increased oxidative stress [31], statins reduce
the risk of major cardiovascular events and all-cause mortality [38].
Conversely, anti-inﬂammatory eﬀects of statins could also explain these
ﬁndings.
In our study, statin users had about half a point lower INFLA score
than non-users. This diﬀerence was primarily due to lower values of
hsCRP and a small diﬀerence in NLR. Bonaccio et al. has shown an
association between higher INFLA score and increased risk of all-cause
mortality [39]; interestingly, hsCRP and NLR were the most important
components of this association. Furthermore, an elevated level of
hsCRP is an established risk factor for CVD [40,41]. Our ﬁndings in this
respect are supported by other similar general population studies
[20–23]. This implies that our study population and statistical models
are comparable to other large general population studies.
A strength of our study is the inclusion of a very large population in
a municipality with both urban and rural areas [25]. It is the ﬁrst
general population study to investigate the associations of statin
treatment with markers of oxidatively generated RNA and DNA da-
mage, and it is currently the largest general population study to in-
vestigate the eﬀect of statin treatment on biochemical markers of in-
ﬂammation. Importantly, the study has power to detect smaller
diﬀerences in 8-oxodG and 8-oxoGuo than previous clinical studies
have had. Furthermore, we used validated biomarkers of oxidatively
Fig. 3. Diﬀerence in inﬂammatory markers between statin
users and non-users by multivariate linear regression
models. A negative diﬀerence represents a lower value of
the marker in statin users compared to non-users. ΔSD:
standard deviation diﬀerence in markers between statin
users and non-users. The models were adjusted for gender,
age, smoking habits, BMI, hip-waist ratio, hypertension,
T2DM, ischemic disease, LDL-C, HDL-C, physical activity
and eGFR. *hsCRP and NLR are log transformed. The
diﬀerence presented in the forest plot is diﬀerence in the
log values. Percentage diﬀerences in the groups are shown
to the right. hsCRP, high sensitivity C-reactive protein;
WBC, white blood cell count; MONO, monocyte count;
NEUT, neutrophil granulocyte count; LYM, lymphocyte
count; NLR, neutrophil lymphocyte ratio; PLT, platelet
count.
A.L. Sørensen et al. Redox Biology 21 (2019) 101088
5
generated nucleotide damage. Detailed information on confounders
was available for this study.
Some limitations must be acknowledged. Firstly, a cross-sectional
design is not optimal for measuring eﬀects of an intervention; we
cannot infer causality on associations. Consequently, the reported as-
sociations and estimates should be interpreted with caution. Secondly,
confounding by indication could be a limitation. Statin users are in-
herently diﬀerent from non-users (Table 1), and after adjustment for
confounders the diﬀerences observed might be aﬀected by better
health-related behavior in statin users, e.g. better compliance or more
aggressive treatment regimes. Thirdly, statin use was assessed using a
self-reported questionnaire asking about medication use for elevated
cholesterol levels. Some participants might not know the indication for
all medications used. Consequently, these participants, who possibly
had increased levels of inﬂammation and oxidatively generated da-
mage, may erroneously be included in the non-user group. Moreover,
we have no information about diﬀerent types and doses of statins. In
2010–2013, the water-soluble types simvastatin and atorvastatin to-
gether accounted for approximately 90% of prescriptions on lipid-
lowering drugs in Denmark, while the lipid-soluble type rosuvastatin
accounted for most of the rest [42]; however, we did not have in-
formation on particular subtypes of lipid modifying agents. Although,
users of lipid-lowering drugs, other than statins, may have been in-
cluded, 98% of lipid-lowering drugs prescribed were statins, according
to the Danish Drug Statistics Register (www.medstat.dk) for
2010–2013, so this source of error is but minor.
Levels of 8-oxoGuo seem to discriminate patients with T2DM for
premature death [43], but the clinical prognostic validity and utility of
the biomarker is still unclear, and needs to be investigated in large
follow-up studies.
5. Conclusions
Oxidatively generated DNA damage and inﬂammatory burden are
lower in statin users compared with non-users. Together, anti-oxidative
and anti-inﬂammatory eﬀects may contribute to the beneﬁcial eﬀects of
statins.
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